Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study

Results from a large-scale, population-based cohort study of more than 107,000 patients with myeloproliferative neoplasms (MPNs) show that patients with MPNs have almost twice the risk of pneumonia and respiratory mortality, compared with those without MPNs. For patients with MPNs, the multivariable adjusted hazard ratios were 2.18 (95% CI: 1.60-2.96) for pneumonia and 2.27 (1.46-3.53) for respiratory mortality.